Albert Gerrit Siebers has a total of 334 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Factors associated with cytology triage attendance after a hrHPV-positive self-sample and age-related differences: The lifelines cohort

    by Ekram S. Jemal, Albert G. Siebers, Ed Schuuring, G. Bea A. Wisman, Geertruida H. De Bock

    Background: Self-sampling for high-risk human papillomavirus (hrHPV) testing has been introduced in cervical cancer screening programs to improve participation. In the Netherlands, women with an hrHPV-positive self-sample are required to visit their GP's office for cytology triage, as this cannot be performed on self-sampled material. Non-attendance at this step reduces screening effectiveness. This study examined whether sociodemographic and health-related behavioural factors commonly associated with screening participation are also associated with cytology triage attendance after an hrHPV-positive self-sample and whether these associations differ by age. Methods: We conducted a study on the Lifelines cohort of participants in the Dutch cervical cancer screening program who used self-sampling between 2017 and 2024. The main outcome was cytology triage attendance within 6 months after an hrHPV-positive self-sample. Lifelines contains data on sociodemographic and behavioural factors including education, income, marital status, smoking, alcohol, diet, body mass index, physical activity, television viewing, sleep duration, lifetime use of hormonal contraception, parity, number of children and age at first childbirth. Logistic regression analyses were performed, including age-stratified models. Results: Among women with an hrHPV-positive self-sample, 10.2% did not attend cytology triage within 6 months. Most sociodemographic and lifestyle factors were not associated with cytology triage attendance, and no meaningful differences were observed between age groups. However, inadequate prior screening history was associated with lower odds of cytology triage attendance. Conclusions: The lack of associations with lifestyle or sociodemographic factors suggest that program-level strategies such as how hrHPV test results are communicated, might be more effective in increasing triage participation than interventions targeting specific subgroups.

  • Healthcare expenditures across the care continuum of pancreatic cancer and resected precursor lesions

    by Marloes Lja Sprij, Brenda J van Stigt, Albert G Siebers, Olivier R Busch, Niels G Venneman, Rogier P Voermans, Eva Kouw, Marco J Bruno, Djuna L Cahen, Iris Lansdorp-Vogelaar, et al.

  • Survival After Fertility-Sparing Surgery for Early-Stage Cervical Cancer Compared With Nonsparing Surgery: A Nationwide Comparative Study

    by Janneke T. Wolswinkel, Petra L.M. Zusterzeel, Anke Smits, Albert G. Siebers, Hans H.B. Wenzel, Ruud L.M. Bekkers, Jogchum J. Beltman, Christianne A.R. Lok, Constantijne H. Mom, Nienke E. van Trommel, et al.

    PURPOSE: The oncologic safety of fertility-sparing surgery in young women with early-stage cervical cancer is largely based on retrospective data from small series, highlighting the need for larger studies to validate its safety. METHODS: We performed a nation-wide retrospective matched cohort study of all patients age 18-45 years with Fédération Internationale de Gynécologie et d’Obstétrique (FIGO) 2018 stage IA1 to IB2 cervical cancer who underwent fertility-sparing surgery (FSS; cone biopsy, large loop excision of the transformation zone, or [radical] trachelectomy) between 2000 and 2022 in the Netherlands (fertility-sparing group). These patients were matched 1:2 with women who had a (radical) hysterectomy for early-stage cervical cancer (hysterectomy group). Patients were matched for pretreatment FIGO 2018 stage, histology, and lymph vascular space invasion. We compared data on recurrence-free survival, disease-free survival, and overall survival (OS) between the fertility-sparing group and the hysterectomy-group. RESULTS: In total, 1,446 patients were included: 482 treated with FSS and 964 with a (radical) hysterectomy; 57.5% had stage 1A1 or 1A2, and 42.5% had IB1 or IB2 cervical cancer. The median follow-up was 8.9 years (IQR, 4.4-13.7). During the study period, 4.8% of patients developed a recurrence: 7.1% in the fertility-sparing group and 3.6% in the hysterectomy group (hazard ratio [HR], 2.21 [95% CI, 1.38 to 3.56]).The OS in both groups did not differ (HR, 1.06 [95% CI, 0.62 to 1.80]). CONCLUSION: Women treated with FSS had a significantly higher recurrence rate than patients who had the uterus completely removed. However, since the increased recurrence rate did not affect OS, fertility-sparing surgery appears to be a potentially safe treatment option.


  • Open Access

    Long-term cervical cancer risk following negative hrHPV-based versus negative cytology-based screening: A population-based study

    by Veerle J.C. Schevenhoven, Erik E.L. Jansen, Albert G. Siebers, Inge M.C.M. de Kok

  • Open Access

    Supplementary Table 1 and Supplementary Figure 1 from Sociodemographic Characteristics and Screening Outcomes of Women Preferring Self-Sampling in the Dutch Cervical Cancer Screening Programme: A Population-Based Study

    by Clare A. Aitken, Federica Inturrisi, Sylvia Kaljouw, Daan Nieboer, Albert G. Siebers, Willem J.G. Melchers, Adriaan J.C. van Den Brule, Anco Molijn, John W.J. Hinrichs, Hubert G.M. Niesters, et al.

    Supplementary Table 1: Birthyears invited for screening in 2017 and 2018. Supplementary Figure 1: Data linkage flowchart, describing how CBS data was linked to PALGA data on an individual level

  • Open Access

    Data from Sociodemographic Characteristics and Screening Outcomes of Women Preferring Self-Sampling in the Dutch Cervical Cancer Screening Programme: A Population-Based Study

    by Clare A. Aitken, Federica Inturrisi, Sylvia Kaljouw, Daan Nieboer, Albert G. Siebers, Willem J.G. Melchers, Adriaan J.C. van Den Brule, Anco Molijn, John W.J. Hinrichs, Hubert G.M. Niesters, et al.

    Background:In the Netherlands, lower high-risk human papillomavirus (hrHPV) positivity but higher cervical intraepithelial neoplasia (CIN) 2+ detection were found in self-collected compared with clinician-collected samples. To investigate the possible reason for these differences, we compared sociodemographic and screening characteristics of women and related these to screening outcomes.Methods:We extracted data from PALGA on all primary hrHPV screens and associated follow-up tests for 857,866 screened women, invited in 2017 and 2018. We linked these data with sociodemographic data from Statistics Netherlands. Logistic regression was performed for hrHPV positivity and CIN 2+/3+ detection.Results:Out of the 857,866 women, 6.8% chose to use a self-sampling device. A higher proportion of self-sampling users was ages 30 to 35 years, was not previously screened, was living in a one-person household, or was the breadwinner in the household. After adjustment for these factors self-sampling had lower hrHPV positivity (aOR, 0.65; 95% CI, 0.63–0.68)) as compared with clinician-collected sampling, as well as lower odds of CIN 2+ (aOR, 0.76; 95% CI, 0.70–0.82) and CIN 3+ (aOR, 0.86; 95% CI, 0.78–0.95) detection.Conclusions:It is likely that the observed differences between the two sampling methods are not only related to sociodemographic differences, but related to differences in screening test accuracy and/or background risk.Impact:Self-sampling can be used for targeting underscreened women, as a more convenient screening tool. Further investigation is required to evaluate how to implement self-sampling, when it is used as a primary instrument in routine screening.See related commentary by Arbyn et al., p. 159

  • Open Access

    The Risk of Developing Cervical Cancer in the Elderly: Who Benefits From Screening After the Age of 60?

    by Renée M.F. Ebisch, Celine Bsc Buijssen, Nicole C.M. Visser, Albert G. Siebers, Ruud L.M. Bekkers

    Objectives: Population-based cervical cancer screening in the Netherlands ends at age 60. This retrospective cohort study aims to identify a subgroup of people over 60 years who are at increased cervical cancer risk, and may benefit from extended screening. Methods: People with a cervix, aged 59–61 with an abnormal exit smear (index smear), conducted as part of the screening program between 2000 and 2004, were identified from the Dutch nationwide pathology databank. A 1:3 matching was obtained with people without an abnormal screening smear at the same age. Incidence rate ratios (IRR) were calculated for the risk of developing cervical cancer or cervical intraepithelial neoplasia (CIN) later in life. Up to 22 years of follow-up was obtained. Results: A total of 10,368 people were identified. The IRR for CIN and cervical cancer was increased for people with an abnormal index smear. This risk was highest for people with a high-grade index smear, compared with a normal index smear; IRR of high-grade CIN of 104.05 (95% CI = 38.18–353.18) and IRR for cervical cancer of 18.58 (95% CI = 5.31–61.07). The majority (82%) of people with an abnormal index test showed normal cytology or histology preceding their CIN or cervical cancer. Conclusions: People with a cervix with abnormal cytology in their exit screening smear 59–61 years showed a 19 times increased lifelong risk of cervical cancer and more than 100 times increased risk for CIN. Because this increased risk was not limited to a specific timeframe, prolonged screening or adjusted diagnostic follow-up for this specific group should be considered.


  • Open Access

    Acceptability of risk-based triage in cervical cancer screening: A focus group study

    by Sharell Bas, Jasmijn Sijben, Erik W. M. A. Bischoff, Ruud L. M. Bekkers, Inge M. C. M. de Kok, Willem J. G. Melchers, Albert G. Siebers, Daniëlle van der Waal, Mireille J. M. Broeders

    Background: Compared to the previous cytology-based program, the introduction of primary high-risk human papillomavirus (hrHPV) based screening in 2017 has led to an increased number of referrals. To counter this, triage of hrHPV-positive women in cervical cancer screening can potentially be optimized by taking sociodemographic and lifestyle risk factors for cervical abnormalities into account. Therefore, it is essential to gain knowledge of the views of women (30–60 years) eligible for cervical cancer screening. Objective: The main goal of this qualitative study was to gain insight in the aspects that influence acceptability of risk-based triage in cervical cancer screening. Design: A focus group study in which participants were recruited via four general medical practices, and purposive sampling was used to maximize heterogeneity with regards to age, education level, and cervical cancer screening experiences. Approach: The focus group discussions were transcribed verbatim and analyzed using reflexive thematic analysis. Participants: A total of 28 women (average age: 45.2 years) eligible for cervical cancer screening in The Netherlands participated in seven online focus group discussions. Half of the participants was higher educated, and the participants differed in previous cervical cancer screening participation and screening result. Key results: In total, 5 main themes and 17 subthemes were identified that determine the acceptability of risk-stratified triage. The main themes are: 1) adequacy of the screening program: an evidence-based program that is able to minimize cancer incidence and reduce unnecessary referrals; 2) personal information (e.g., sensitive topics and stigma); 3) emotional impact: fear and reassurance; 4) communication (e.g., transparency); and 5) autonomy (e.g., prevention). Conclusion: The current study highlights several challenges regarding the development and implementation of risk-based triage that need attention in order to be accepted by the target group. These challenges include dealing with sensitive topics and a transparent communication strategy.


  • Open Access

    Sociodemographic Characteristics and Screening Outcomes of Women Preferring Self-Sampling in the Dutch Cervical Cancer Screening Programme: A Population-Based Study

    by Clare A. Aitken, Federica Inturrisi, Sylvia Kaljouw, Daan Nieboer, Albert G. Siebers, Willem J. G. Melchers, Adriaan J. C. van Den Brule, Anco Molijn, John W. J. Hinrichs, Hubert G. M. Niesters, et al.

    Background: In the Netherlands, lower high-risk human papillomavirus (hrHPV) positivity but higher cervical intraepithelial neoplasia (CIN) 2+ detection were found in self-collected compared with clinician-collected samples. To investigate the possible reason for these differences, we compared sociodemographic and screening characteristics of women and related these to screening outcomes. Methods: We extracted data from PALGA on all primary hrHPV screens and associated follow-up tests for 857,866 screened women, invited in 2017 and 2018. We linked these data with sociodemographic data from Statistics Netherlands. Logistic regression was performed for hrHPV positivity and CIN 2+/3+ detection. Results: Out of the 857,866 women, 6.8% chose to use a self-sampling device. A higher proportion of self-sampling users was ages 30 to 35 years, was not previously screened, was living in a one-person household, or was the breadwinner in the household. After adjustment for these factors self-sampling had lower hrHPV positivity (aOR, 0.65; 95% CI, 0.63–0.68)) as compared with clinician-collected sampling, as well as lower odds of CIN 2+ (aOR, 0.76; 95% CI, 0.70–0.82) and CIN 3+ (aOR, 0.86; 95% CI, 0.78–0.95) detection. Conclusions: It is likely that the observed differences between the two sampling methods are not only related to sociodemographic differences, but related to differences in screening test accuracy and/or background risk. Impact: Self-sampling can be used for targeting underscreened women, as a more convenient screening tool. Further investigation is required to evaluate how to implement self-sampling, when it is used as a primary instrument in routine screening. See related commentary by Arbyn et al., p. 159


  • Open Access

    Endometrial Cancer Incidence in Endometriosis and Adenomyosis

    by Marjolein Hermens, Anne M. van Altena, Iris Velthuis, Danielle C. M. van de Laar, Johan Bulten, Huib A. A. M. van Vliet, Albert G. Siebers, Ruud L. M. Bekkers

    Women with histologically proven endometriosis/adenomyosis have an increased risk of ovarian cancer. Small studies show conflicting results on the endometrial cancer risk in women with endometriosis/adenomyosis. Therefore, we assessed the incidence of endometrial cancer in women with histologically proven endometriosis or adenomyosis. We performed a population-based retrospective cohort study of 129,862 women with histologically proven endometriosis/adenomyosis, matched with 132,700 women with a nevus selected from the Dutch pathology registry between 1990 and 2015. Histology results for endometrial cancer were retrieved. Crude and age-adjusted odds ratios for endometrial cancer were estimated. In the endometriosis/adenomyosis group, 1827 (1.4%) women had a histological report on endometrial cancer, and in the nevus group, 771 (0.6%) women. The age-adjusted OR for endometrial cancer was 2.58 (95%CI 2.37–2.81). After excluding the first year of follow-up, the age-adjusted OR was 0.76 (95%CI 0.63–0.92), indicating that endometrial cancer is most often found at time of histological diagnosis of endometriosis/adenomyosis. In around 20% of the endometrial cancer cases, the endometrial cancer was not recognized until after hysterectomy. Of these women, 35% had no prior (micro)curettage or biopsy. This study shows an increased incidence of endometrial cancer in women with histologically proven endometriosis and adenomyosis.